Enable Accessibility Enable Accessibility

Takeda Announces New Global Operating Structure and Changes to Reporting Lines Under Chief Operating Officer from April 1st

March 13, 2014

Osaka, Japan, March 13, 2014 – Takeda Pharmaceutical Company Limited (Takeda) today announced organization and reporting line changes to be effective upon the arrival of Mr. Christophe Weber as Takeda's Chief Operating Officer (COO) as of April 1, 2014. Upon this date, Mr. Weber will be responsible for all operational activities and report to Mr. Yasuchika Hasegawa as Takeda's President & Chief Executive Officer (CEO). Specifically, all functions and divisions currently reporting to the President & CEO will report directly to Mr. Weber as COO. These steps are designed to create a truly global operating structure and achieve performance that meets the highest global standards. 

Furthermore, Takeda's commercial operations outside Japan and the Vaccine Business Division will report directly to the COO. Mr. Weber has vast experience in commercial operations across a variety of geographies and pharmaceutical product areas including vaccines. This elevation of the reporting line to the COO is an indication of the great importance Takeda places on its global commercial operations. In addition, the Office of the President & CEO will be integrated into the Corporate Strategy Department in order to provide highly effective strategic and operational support to the President & CEO as well as the COO.

As a result of the new direct reporting line from commercial operations to the COO, Takeda will no longer have the position of Chief Commercial Officer (CCO) and the current CCO, Dr. Frank Morich, has decided to step down effective April 1, 2014. Dr. Morich's exceptional contribution to the company as an inaugural member of the Takeda Global Advisory Board and later as Director and CCO include the successful acquisition and subsequent integration of Nycomed. Dr. Morich has elected take early retirement from the board after the Ordinary General Meeting of Shareholders scheduled in June 2014.

Takeda’s mission is to strive towards better health for people worldwide through leading innovation in medicine and continue to transform into a truly global pharmaceutical company that responds to the diverse medical needs around the world while at the same time fulfilling its obligations to stakeholders.